- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03558867
Medicina Personalizada en Prediabetes y Diabetes Tipo 2 Temprana (PREDICT)
Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk
Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.
Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.
The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.
Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.
Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.
While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.
Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- Garvan Institute of Medical Research
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
- Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
- Willingness to provide written informed consent and willingness to participate and comply with the study.
Exclusion Criteria:
- Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
- Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
- Liver enzymes ALT and/or AST>3-times normal range limit.
- Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
- Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
- Normo-glycaemia.
- HbA1c>8.0%
- Cardiovascular event in the previous 6 months.
- Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
- Current or recent (within 3 months) treatment with metformin.
- Treatment with an oral steroid.
- Treatment with antibiotics in the last 3 months.
- Treatment with immunosuppressive medications.
- Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
- Substance abuse.
- Participants who had received an investigational new drug within the last 6 months.
- Participants involved in another clinical study.
- Participants who actively lose weight.
- Participants who had a bariatric surgery.
- Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Metformin + Healthy diet
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet |
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
Otros nombres:
|
|
Comparador activo: Metformin + Personalized diet
Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015) |
Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean change in glycated haemoglobin (HbA1C, %) from baseline
Periodo de tiempo: 6 months
|
Difference in the reduction of HbA1C between the groups |
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
Periodo de tiempo: 6 months
|
Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups |
6 months
|
|
Glycaemic variability
Periodo de tiempo: 6 months
|
Difference in the glycaemic variability as derived from CGM between the groups |
6 months
|
|
Body weight
Periodo de tiempo: 6 months
|
Difference in the magnitude of weight loss between the groups |
6 months
|
|
Body fat mass
Periodo de tiempo: 6 months
|
Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups |
6 months
|
|
Abdominal visceral fat volume
Periodo de tiempo: 6 months
|
Difference in the abdominal visceral fat volume as assessed using DXA between the groups |
6 months
|
|
Serum low-density lipoprotein (LDL)-cholesterol concentration
Periodo de tiempo: 6 months
|
Difference in serum LDL-cholesterol between the groups |
6 months
|
|
Serum high-density lipoprotein (HDL)-cholesterol concentration
Periodo de tiempo: 6 months
|
Difference in serum HDL-cholesterol concentration between the groups |
6 months
|
|
Serum triglycerides concentration
Periodo de tiempo: 6 months
|
Difference in serum triglycerides between the groups |
6 months
|
|
Blood pressure
Periodo de tiempo: 6 months
|
Difference in diastolic and systolic blood pressure between the groups |
6 months
|
|
Liver fat
Periodo de tiempo: 6 months
|
Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups |
6 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gut microbiome (exploratory)
Periodo de tiempo: 6 months
|
Difference in gut microbiome features between the groups |
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Dorit Samocha-Bonet, PhD, Garvan Institute of Medical Research
- Investigador principal: Jerry Greenfield, MD, PhD, Garvan Institute of Medical Research
- Investigador principal: Eran Elinav, MD, PhD, Weizmann Institute of Science
- Investigador principal: Eran Segal, PhD, Weizmann Institute of Science
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Hiperinsulinismo
- Hiperglucemia
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 2
- Resistencia a la insulina
- Intolerante a la glucosa
- Químicos orgánicos
- Terapéutica
- Dieta, alimentos y nutrición
- Fenómeno fisiológico
- Fenómenos fisiológicos nutricionales
- Terapia de dieta
- Terapia nutricional
- Biguanides
- Guanidinas
- Amidinos
- Metformina
- Dieta
- Dieta, saludable
- Dieta, restringida
Otros números de identificación del estudio
- SVH 17/080
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .